206 related articles for article (PubMed ID: 15498563)
1. The SEP domain of p47 acts as a reversible competitive inhibitor of cathepsin L.
Soukenik M; Diehl A; Leidert M; Sievert V; Büssow K; Leitner D; Labudde D; Ball LJ; Lechner A; Nägler DK; Oschkinat H
FEBS Lett; 2004 Oct; 576(3):358-62. PubMed ID: 15498563
[TBL] [Abstract][Full Text] [Related]
2. Human cathepsin X. A novel cysteine protease with unique specificity.
Ménard R; Nägler DK; Zhang R; Tam W; Sulea T; Purisima EO
Adv Exp Med Biol; 2000; 477():317-22. PubMed ID: 10849759
[No Abstract] [Full Text] [Related]
3. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.
Guay J; Falgueyret JP; Ducret A; Percival MD; Mancini JA
Eur J Biochem; 2000 Oct; 267(20):6311-8. PubMed ID: 11012686
[TBL] [Abstract][Full Text] [Related]
4. The slow-binding inhibition of cathepsin K by its propeptide.
Billington CJ; Mason P; Magny MC; Mort JS
Biochem Biophys Res Commun; 2000 Oct; 276(3):924-9. PubMed ID: 11027570
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of the collagenolytic activity of human cathepsin K by altering its S2 subsite specificity.
Lecaille F; Choe Y; Brandt W; Li Z; Craik CS; Brömme D
Biochemistry; 2002 Jul; 41(26):8447-54. PubMed ID: 12081494
[TBL] [Abstract][Full Text] [Related]
6. Human proteoglycan testican-1 inhibits the lysosomal cysteine protease cathepsin L.
Bocock JP; Edgell CJ; Marr HS; Erickson AH
Eur J Biochem; 2003 Oct; 270(19):4008-15. PubMed ID: 14511383
[TBL] [Abstract][Full Text] [Related]
7. Bombyx cysteine proteinase inhibitor (BCPI) homologous to propeptide regions of cysteine proteinases is a strong, selective inhibitor of cathepsin L-like cysteine proteinases.
Kurata M; Yamamoto Y; Watabe S; Makino Y; Ogawa K; Takahashi SY
J Biochem; 2001 Dec; 130(6):857-63. PubMed ID: 11726287
[TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of a cathepsin L-like cysteine protease by a chimeric propeptide-derived inhibitor.
Godat E; Chowdhury S; Lecaille F; Belghazi M; Purisima EO; Lalmanach G
Biochemistry; 2005 Aug; 44(31):10486-93. PubMed ID: 16060657
[TBL] [Abstract][Full Text] [Related]
10. Saxiphilin, a saxitoxin-binding protein with two thyroglobulin type 1 domains, is an inhibitor of papain-like cysteine proteinases.
Lenarcic B; Krishnan G; Borukhovich R; Ruck B; Turk V; Moczydlowski E
J Biol Chem; 2000 May; 275(20):15572-7. PubMed ID: 10748022
[TBL] [Abstract][Full Text] [Related]
11. Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L.
Brömme D; Klaus JL; Okamoto K; Rasnick D; Palmer JT
Biochem J; 1996 Apr; 315 ( Pt 1)(Pt 1):85-9. PubMed ID: 8670136
[TBL] [Abstract][Full Text] [Related]
12. Amino acid substitutions in the N-terminal segment of cystatin C create selective protein inhibitors of lysosomal cysteine proteinases.
Mason RW; Sol-Church K; Abrahamson M
Biochem J; 1998 Mar; 330 ( Pt 2)(Pt 2):833-8. PubMed ID: 9480898
[TBL] [Abstract][Full Text] [Related]
13. The propeptide of Fasciola hepatica cathepsin L is a potent and selective inhibitor of the mature enzyme.
Roche L; Tort J; Dalton JP
Mol Biochem Parasitol; 1999 Jan; 98(2):271-7. PubMed ID: 10080395
[No Abstract] [Full Text] [Related]
14. Identification and characterization of a cathepsin L-like cysteine protease from Gnathostoma spinigerum.
Kongkerd N; Uparanukraw P; Morakote N; Sajid M; McKerrow JH
Mol Biochem Parasitol; 2008 Aug; 160(2):129-37. PubMed ID: 18554733
[TBL] [Abstract][Full Text] [Related]
15. Partial characterization of a novel cathepsin L-like protease from Fasciola hepatica.
Hawthorne SJ; Pagano M; Halton DW; Walker B
Biochem Biophys Res Commun; 2000 Oct; 277(1):79-82. PubMed ID: 11027643
[TBL] [Abstract][Full Text] [Related]
16. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
[TBL] [Abstract][Full Text] [Related]
17. Cathepsins X and B can be differentiated through their respective mono- and dipeptidyl carboxypeptidase activities.
Therrien C; Lachance P; Sulea T; Purisima EO; Qi H; Ziomek E; Alvarez-Hernandez A; Roush WR; Ménard R
Biochemistry; 2001 Mar; 40(9):2702-11. PubMed ID: 11258881
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of collagenolytic cathepsins by beta-lactoglobulin in milk and its suppressive effect on bone resorption.
Ogawa N; Takahashi M; Ishidoh K; Katunuma N
J Nutr Sci Vitaminol (Tokyo); 2009 Jun; 55(3):264-70. PubMed ID: 19602835
[TBL] [Abstract][Full Text] [Related]
19. Development of peptidyl alpha-keto-beta-aldehydes as new inhibitors of cathepsin L--comparisons of potency and selectivity profiles with cathepsin B.
Lynas JF; Hawthorne SJ; Walker B
Bioorg Med Chem Lett; 2000 Aug; 10(15):1771-3. PubMed ID: 10937745
[TBL] [Abstract][Full Text] [Related]
20. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
